Southeast University, Nanjing, People's Republic of China. guoqiu
Peptides. 2011 Feb;32(2):353-7. doi: 10.1016/j.peptides.2010.10.029. Epub 2010 Nov 2.
Sepsis continues to be a major unresolved medical challenge of the present. Severe sepsis and septic shock are the leading causes of multiple organ failure and mortality in noncoronary intensive care units (ICUs). The primary reason of septic shock is the activation of host effecter cells by endotoxin and lipopolysaccharide (LPS) associated with cell membranes of gram-negative bacteria. For these reasons, the key point of treatment is removing LPS. S-thanatin (Ts), an analog of thanatin, was synthesized by substituting the 15th amino acid of threonine with serine, which showed a broad antimicrobial activity against gram-negative and gram-positive bacteria. We have reported its LPS-binding and -neutralizing activity in vitro. The aim of this study is to examine the LPS-neutralizing activities and the protective effects of S-thanatin in vivo. Every mice was injected intraperitoneally with LPS (from Escherichia coli O111:B4) 150μg before injected intraperitoneally or vena caudalis with 3mg/kg, 6mg/kg and 12mg/kg, and measured endotoxin and tumor necrosis factor alpha (TNF-α) concentrations in plasma, as well as lethality. The results showed that S-thanatin can significantly reduce endotoxin and TNF-α level in plasma, at the same time resulting in the highest survival rates.
脓毒症仍然是目前尚未解决的主要医学挑战之一。严重脓毒症和感染性休克是非冠状动脉重症监护病房(ICU)多器官衰竭和死亡的主要原因。感染性休克的主要原因是内毒素和脂多糖(LPS)与革兰氏阴性菌细胞膜相关,激活宿主效应细胞。出于这些原因,治疗的关键是去除 LPS。S-Thanatin(Ts)是 Thanatin 的类似物,通过用丝氨酸取代苏氨酸的第 15 个氨基酸合成,对革兰氏阴性菌和革兰氏阳性菌具有广泛的抗菌活性。我们已经在体外报告了其 LPS 结合和中和活性。本研究旨在研究 S-Thanatin 的 LPS 中和活性及其体内保护作用。每只小鼠在腹腔内注射 LPS(来自大肠杆菌 O111:B4)150μg 后,分别腹腔内或尾静脉注射 3mg/kg、6mg/kg 和 12mg/kg,并测量血浆中的内毒素和肿瘤坏死因子-α(TNF-α)浓度以及死亡率。结果表明,S-Thanatin 可显著降低血浆中的内毒素和 TNF-α 水平,同时使存活率达到最高。